African TB
Meeting category
Date(s)
3 Jul 2024 - 4 Jul 2024
Location
Kampala, Uganda
Meeting type
Live meeting
Organizer

Conference on Innovations in Tuberculosis 2024

Related Enduring Materials

Enduring Materials

Download Program

Download Program Book

Download Abstract Book

The presentation videos and slides for speakers’ lectures are made available, provided that they have granted us permission to do so.

Day 1 - Wednesday, 3 July 2024
Session 1: National TB Control Programs: Where Do We Stand? -
National Program: Zambia
Chitalu Chanda
Ministry of Health, University Teaching Hospital, Zambia
National Program: Mozambique
Celso Khosa, MD, PhD
Instituto Nacional de Saúde, Mozambique
An Introductory Overview
Stavia Turyahabwe, MBChB, MPH
Ministry of Health, Uganda
At the Interface of Research and Policies
Nilesh Bhatt, MD, MMED, PhD
Elizabeth Glaser Pediatric AIDS Foundation, Mozambique
Panel Discussion: What are the Barriers?
Session 2: Diagnostics -
Novel Algorithms, AI, and Community Contact Tracing
Achilles Katamba, MBChB, DCH, MSc PhD
Makerere University College of Health Sciences, Walimu, Uganda
#1 - Finding the Missing Tuberculosis Cases: Lessons Learnt From Using Artificial Intelligence Enabled Chest X-Ray System for Active TB Case Search in Communities in Lagos, Nigeria
Taiwo Osatuyi
Nigeria
#3 - Introduction of X-MAP System in Bridging the Evaluation Gap in Using AI Enabled Systems for Active Case Search in Lagos, Nigeria
Taiwo Osatuyi
Nigeria
Discussion
Session 3: Pediatric Tuberculosis -
TB in Children
Chishala Chabala, MBChB, MSc, MMed
University of Zambia, School of Medicine, Zambia
#4 - Diagnostic Cascade Using New WHO Pediatric Treatment Decision Algorithms for Pulmonary TB in Mbarara, Uganda
Maria Namulwana
Uganda
#5 - Nigeria Addressing the Challenges in Childhood Tuberculosis Diagnosis With Stool-Based Xpert Testing to Improve Childhood TB Detection Rates
Omotayo Salau
Nigeria
# 6 - The Use of ONEIMPACT-Nigeria as a Digital Health Platform and Innovative Strategy to Improve Tuberculosis Preventive Therapy Uptake in Children in Lagos, Nigeria
Deborah Iberi Ikeh
Nigeria
Discussion
Session 4: TB, Comorbidities and Co-Infections -
HIV and TB
Esther Stanslaus Ngadaya, PhD, PGDHE, MD
National Institute for Medical Research, Muhimbili Research centre (NIMR-Muhimbili), Tanzania
#7 - The Burden of Tuberculous Meningitis in Greater Masaka Region-Southwestern Uganda: Findings From the Alter Trial
Maria Assumpta Nakimbugwe
Uganda
#9 - Utilizing a Model for Improvement Framework to Improve the Specificity of the WHO-Recommended 4-Symptom-Screen for Tuberculosis Diagnosis Among People Living With HIV in Nigeria
Emeka Ezieke
Nigeria
Discussion
Day 2 - Thursday, 4 July 2024
Session 5: Prevention -
Preventative Treatment
Nyanda Elias Ntinginya, MD, MSc, PhD
National Institute for Medical Research (NIMR), Tanzania
Post-TB Lung Diseases
Celso Khosa, MD, PhD
Instituto Nacional de Saúde, Mozambique
TB Vaccines on the Horizon
Frank Cobelens, MD, MSc, PhD
Amsterdam University Medical Centres, University of Amsterdam / Amsterdam Institute for Global Health and Development, The Netherlands
#11 - Prediction Models for Mtb Infection Among Adolescent and Adult Household Contacts in High TB Incidence Settings
Edson Tawanda Marambire
Germany
FAST-TB Supported Session - Innovative Approaches in Conducting Clinical Trials for new TB Treatments -
Clinical Trial 1: PAN-TB
Andreas H. Diacon, MD, PhD
TASK, South Africa
Clinical Trial 3: PARADIGM4TB
Nyanda Elias Ntinginya, MD, MSc, PhD
National Institute for Medical Research (NIMR), Tanzania
Discussion: Innovative Approaches in Conducting Clinical Trials
Session 7: Innovations in Implementation Strategies -
#13 - Enhancing TB Contact Investigation: Finding the Missing TB Cases Using the Spot to Tent Onion Model
Iboro Gordon
Nigeria
#14 - Artificial Intelligence (AI) screening for TB as an Effective Tool for GeneXpert (GXP) Cartridge Optimization: Comparing TB Yield From Community Active Case Finding (CACF) With and Without PDX with AI in Benue State
Eze Chukwu
Nigeria
#15 - Artificial Intelligence for TB Screening to Improve Active TB Case Detection Among Urban Slum, Rural and Pastoralist TB-Key Affected and Vulnerable Populations in Ethiopia.
Tamiru Mebrate
Ethiopia
#16 - Patient-Centered Innovations in TB Care: A Case Study of Digital Adherence Technologies Project in Nigeria
Iboro Gordon
Nigeria
Discussion: Community-led Services
Session 9: MDR-TB: What is on the Horizon? -
Treatment Studies
Francesca Conradie, MBBCh
WHO, Switzerland
Innovative Tools to Study Emerging Drug Resistance
Celso Khosa, MD, PhD
Instituto Nacional de Saúde, Mozambique
Program Implications
Debrah Vambe, MD, MPhil, MPH
Baylor College of Medicine, Global and Immigrant Health, Eswatini
Discussion
General
What's New
About this Program

The Conference on Innovations in Tuberculosis 2024 took place from 3-4 July as a live meeting in Kampala, Uganda.

Tuberculosis (TB) caused 1.6 million deaths in 2021, being the leading cause of death among infectious diseases, above HIV. Yet, it is a curable and preventable disease. While a quarter of the global population has been infected, only 5-10 % of infected individuals develop symptoms. The highest burden regions are South-East Asia, Africa, and the Western Pacific. This bacterial disease is treated by a long course of antibiotics. Nevertheless, for Multidrug-resistant TB (MDR-TB) treatment options are limited, and MDR-TB remains a public health crisis and a health security threat.

TB is a priority on the global health agenda. Orchestrated actions of national and global leadership, researcher organizations, and civil societies strive to achieve a world free of TB. Towards this goal, equitable access to prevention, testing, treatment, and care remains a challenge. On the other hand, we are witnessing encouraging new tools to curb TB. A recent study demonstrated a remarkable reduction in TB transmission due to nutritional supplements offered to household contacts, providing an evidence-based approach to intervene with structural determinants of TB, such as malnutrition. On the biomedical side, a historical milestone seems to be within close range, with the late-stage clinical evaluation of a vaccine to prevent a pulmonary form of TB in adolescents and adults, developed by the Gates Foundation. In parallel, new treatment guidelines on 6-month all-oral regimens for MDR-TB offer simplified treatment options for those patients.   

Yet these exciting developments and innovations are mainly discussed at major international meetings. This, in turn, offers limited space for researchers and healthcare professionals from high-burden countries in Africa, and restricts discussions tailored to regional epidemiological situations, healthcare, and societal contexts. To this end, we propose a platform to disseminate clinically relevant innovations and discuss their translation and implementation in Africa, considering region-specific epidemic patterns, available prevention, testing and treatment options, and healthcare settings.

Local Chairs
General Information 
Uniques Features
• Plenary lectures
• Abstracts
• Poster-viewing sessions
• Capacity-building sessions
• Mentoring Sessions
• Roundtable discussions
• Pro-con debates
• Networking Opportunities
• Exhibition
Who Should Attend?
• Clinical and translational researchers
• Epidemiologists and public health experts
• Program implementers
• (Non)Government representatives
• Health authorities
• Residents, and post-graduate students
• Advocates and community representatives
• Industry representatives
Meeting Objectives
Our goal is to deliver a high-quality program on innovations in Tuberculosis with an emphasis on region-specific needs. We aim to provide a platform for scientific interchange, education, and fostering collaborations to advance the field. More specifically, the program is aimed to:

- Create an African dissemination platform for an unbiased, scientific exchange and education regarding clinically relevant advances in Tuberculosis;

- Provide educational settings to discuss the clinical translation of recent developments considering regional epidemic patterns and healthcare systems;

- Share real-world experience and facilitate evidence-based program implementation;

- Foster new and lasting cross-disciplinary collaborations aiming to strengthen Tuberculosis research and management in high-disease-burden regions;

- Encourage early-career investigators to actively participate in the program and support their career trajectory toward future leaders in Tuberculosis research.
Practical Information 
Venue
The venue will be announced closer to the Conference.
Accommodation
Accommodation is not included in the registration fee.
Badges
All participants are requested to wear the badge at all times during the Conference to ensure admission to the meeting.
Certificate of Attendance
A certificate of attendance will be sent to you after successfully completing the program and post-conference survey.
Language
The official language of the workshop is English.
Enduring Materials
Enduring materials will be available to all registered delegates on the website 3 weeks after the conference. After this, all presentations will be made publicly available on this website (pending the approval of the speakers).
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and Insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Photographs, Audio, and Video Recording
Photographs, audio, and video recordings are not permitted at the official conference sessions. Only the official medical writer appointed by the organization may make recordings. All presentations will be posted here as soon as possible after the workshop is finished, provided the speaker has given permission to do so.
Code of Conduct
All attendees, speakers, co-organizers, partners, endorsers, suppliers, volunteers, and employees at any of our programs are expected to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. All participants of VE and AME-organized programs are expected to treat others with dignity and respect at all times.

Any individual who feels discriminated against, harassed, disrespected, or marginalized is encouraged to report the incident(s) to VE and AME via info@amededu.com or to one of our on-site personnel.
Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.
Committees
The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the conference, identify interesting topics and candidate speakers, and review all submitted abstracts.
Local Chairs
Organizing Committee
Frank Cobelens
Frank Cobelens, MD, MSc, PhD
Amsterdam University Medical Centres, University of Amsterdam / Amsterdam Institute for Global Health and Development, The Netherlands
Scientific Program Coordinator

The members of Scientific Committee are hand-picked by the Organizing Committee (OC) and the conference secretariat based on their significant contributions and commitment to the field. They assist the OC by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the conference as moderators and/or chairs of sessions.

  • Amsalu Bekele Binegdie, MD, College of Health Sciences, Addis Ababa University, Ethiopia
  • John Bimba, PhD, Bingham University, Nigeria
  • Maryline Bonnet, MD, PhD, The French National Research Institute for Sustainable Development (IRD), the University of Montpellier and the National Institute of Health and Medical Research, Montpellier, France, Mbarara University of Science and Technology in MBarara, Uganda 
  • Jeremiah Chakaya Muhwa, MBChB, MMeD, DThM, Kenyatta University, Respiratory Society of Kenya, Kenya 
  • Novel Chegou, BMLS (Hons), BSc. Hons., PhD, Stellenbosch University, South African Medical Research Council Centre for Tuberculosis Research, Stellenbosch University, South Africa
  • Joel Fleury Djoba Siawaya, PhD, HDR, Mother and Child University Hospital, Gabon
  • Thandi J.N Dlamini-Miti, MBBCh, Msc, Isango Lethemba TB Research Unit, Nakekelwa Medical Institute, South Africa
  • Alberto García-Basteiro, MD, PhD, Barcelona Institute for Global Health (ISGlobal), Spain, Centro de Investigação em Saúde de Manhiça (CISM), Mozambique
  • Norbert Heinrich, MD, LMU University Hospital, Germany
  • Bouke de Jong, MD, PhD, Institute of Tropical Medicine, Belgium
  • Celso Khosa, MD, PhD, Instituto Nacional de Saúde, Mozambique
  • Andre Loxton, PhD, SAMRC and Stellenbosch University, South Africa
  • Sayoki G Mfinanga, MD,PhD, Liverpool School Tropical Medicine, University Collage London, England, Nelson Mandela African Institution of Science and Technology (NM-AIST), The Muhimbili University of Health and Allied Sciences, Tanzania
  • Lloyd MulengaBScHb, MBChB, MSc, MMed, PhD, Ministry of Health, Zambia
  • Esther Stanslaus Ngadaya, MD, PGDHE, PhD, National Institute for Medical Research (NIMR), Kampala National University, Tanzania
  • Abel Nkolo, MBChB, MPH, PhD, Africa and LAC Region, Uganda
  • Nyanda Elias Ntinginya, MD, Msc, PhD, National Institute for Medical Research (NIMR), Tanzania
  • Issa Sabi, MD, MMed, PhD, Mbeya Medical Research Center, National Institute for Medical Research (NIMR), Tanzania
  • Simon Walusimbi, MD, MSc, PhD, Makerere University School of Public Health and Lung Institute, Uganda
Endorsers
Support

Support Our Initiative
Financial backing helps us deliver an impactful meeting experience to the benefit of healthcare professionals and researchers interested in the Conference on Innovations in Tuberculosis.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.

To show your commitment to the cause, get in touch with us for a tailored
support package by contacting Kim Go at kim.go@amededu.com.
 
Benefits of Support
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgement during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgement on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgement on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
*Subject to the support level.

Language